Theralase adds omitted Adstiladrin safety, prescribing details in corrected Q2 2026 release

Bitget2026/09/18 11:01

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Theralase issued a corrected replacement of its Q2 2026 financial statements, adding omitted safety and prescribing information for Adstiladrin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609180700NEWSFILECNPR____20260918_314778_1) on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Theralase adds omitted Adstiladrin safety, prescribing details in corrected Q2 2026 release

You may also like

Crypto prices